跳转至内容
Merck
CN
  • Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Neurocritical care (2011-11-01)
Erica H Z Wang, Vincent H Mabasa, Gabriel W Loh, Mary H H Ensom
摘要

Delirium is the most common mental disturbance in critically-ill patients and results in significant morbidity and mortality. Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects. Despite its widespread use in the critical care setting, most of the relevant data are obtained from case series or extrapolated from non-critically-ill populations. This review provides an overview of haloperidol pharmacokinetics and a comprehensive summary of the evidence for various haloperidol dosing regimens in the treatment of delirium in critically-ill patients. A comprehensive literature search was conducted in Medline, Embase, and International Pharmaceutical Abstracts with "haloperidol", "delirium", "agitation", "critically-ill", and "intensive care" as keywords. Studies involving haloperidol for delirium prophylaxis, non-critical care settings, and terminally-ill subjects were excluded. Eleven studies were identified: four with intermittent IV haloperidol, four with continuous IV infusion haloperidol, two with oral/enteral haloperidol, and one with IM haloperidol. All of the case reports, case series, and descriptive studies have shown a benefit with haloperidol, but publication bias is likely present. Only three studies were controlled studies, but all had small sample sizes and methodological flaws. Randomized, double-blind, active-comparator trials of haloperidol with allocation concealment are needed. Subsequent research should focus on using validated delirium screening and assessment scales for more objective identification and measurement of delirium outcomes.

材料
货号
品牌
产品描述

Sigma-Aldrich
氟哌啶醇, powder
货号
包装规格
是否有货
价格
数量
Supelco
Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
货号
包装规格
是否有货
价格
数量
USP
氟哌啶醇, United States Pharmacopeia (USP) Reference Standard
货号
包装规格
是否有货
价格
数量
氟哌啶醇, European Pharmacopoeia (EP) Reference Standard
货号
包装规格
是否有货
价格
数量
系统适用性试验用氟哌啶醇, European Pharmacopoeia (EP) Reference Standard
货号
包装规格
是否有货
价格
数量
峰鉴别用氟哌啶醇, European Pharmacopoeia (EP) Reference Standard
货号
包装规格
是否有货
价格
数量